A Caltech Library Service

A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors

Oliver, J. C. and Yen, Y. and Synold, T. W. and Schluep, T. and Davis, M. (2008) A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors. Journal of Clinical Oncology, 26 (15). Art. No. 14538. ISSN 1527-7755. doi:10.1200/jco.2008.26.90150.14538.

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item:


Background: IT-101 is the first de novo designed experimental nanoparticle therapeutic for cancer and is comprised of a cyclodextrin-based polymer conjugate of camptothecin (CPT) that self-assembles into nanoparticles with diameter of ca. 40 nm and near neutral surface charge. The nanoparticle properties have been designed to accomplish extended circulation, tumor penetration, and slow intracellular drug release to enhance the mechanism of action of the CPT. Methods: Patients with refractory solid tumors received IT-101 by 90 minute IV infusions on days 1, 8, and 15 of a 28 day cycle over a dose range of 6 mg/m^2/wk to 18 mg/m^2/wk. Dose escalation was conducted with a Simon’s design. Dose limiting toxicity (DLT) was determined over the first cycle. Progressive disease (PD) was defined by RECIST (CT) results. Pharmacokinetics of free and total CPT in blood and urine were collected over after the 1st dose. Patients completing 6 cycles with stable disease (SD) or better were eligible to receive compassionate IT-101 at the same dose level every other week (QOW). Results: Twelve patients [6 (6 mg/m^2), 3 (12 mg/m^2), and 3 (18 mg/m^2)] were enrolled. 4 of 12 (33%) had PD by CT. 8 of 12 (66%) did not have PD. (6-SD and 2 clinical deterioration (CD). Hematologic toxicity was the DLT. The MTD was < 30 mg/m^2/mo. In patients receiving > 2 cycles, SD was observed at cumulative doses of 18 mg/m^2/mo to 27 mg/m^2/mo. Three patients (pancreatic, renal cell, NSCLC) completed 6 cycles and received treatment QOW with a PFS of ≥18, 14, and 11 months, respectively. Over 7 days, the mean plasma total CPT and free CPT t_(½ β) were 39 ± 1.1 and 51 ± 1.5 hrs, respectively. The AUC of free and total CPT were linear with 9.9 ± 4.0 % of the CPT dose free. Urinary excretion averaged 16 ± 9.1% of the total CPT dose in the first 48 hrs. Conclusions: These data appear to demonstrate that IT-101 is safe, tolerable, and is associated with acceptable toxicity at the MTD. SD was maintained in patients treated beyond 6 cycles QOW at doses of 6 to 9 mg/m^2/wk. In addition, twice monthly regimens maintained SD with minimal drug-related toxicity. A QOW schedule (allowing for 99% elimination of CPT) is warranted in future clinical trial.

Item Type:Article
Related URLs:
URLURL TypeDescription
Yen, Y.0000-0003-0815-412X
Davis, M.0000-0001-8294-1477
Additional Information:© 2008 American Society of Clinical Oncology.
Issue or Number:15
Record Number:CaltechAUTHORS:20170104-135213212
Persistent URL:
Official Citation:10.1200/jco.2008.26.90150.14538 Journal of Clinical Oncology 26, no. 90150 (May 2008) 14538-14538
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:73216
Deposited By: Tony Diaz
Deposited On:04 Jan 2017 22:02
Last Modified:11 Nov 2021 05:13

Repository Staff Only: item control page